A Phase 3 interventional study of Eptinezumab and Placebo in Migraine, sponsored by H. Lundbeck A/S. Completed at 138 sites in 17 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-09-29.
Sponsored by H. Lundbeck A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing eptinezumab in Migraine Disorders — 6 open to participants now, 6 under way, 5 of them phase 3. eptinezumab · Migraine Disorders.
Among the 21 studies testing eptinezumab in Migraine Disorders, this one is the 4th largest by enrollment, is one of 2 that started in 2020, is one of 13 in phase 3, and was the 8th registered.
1,658 studies on the registry are indexed under Migraine Disorders; 339 are open to participants now.
Browse Migraine Disorders studies →6 of the 21 studies testing eptinezumab in Migraine Disorders are open now, in 11 countries. Recruiting first, the newest first:
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18–65
H. Lundbeck A/S · Sites in United States, Argentina, Canada and 8 more countries
Ages 6–17
H. Lundbeck A/S · Sites in United States, Argentina, Canada and 8 more countries
Ages 6–17
H. Lundbeck A/S · Sites in United States, Argentina, Canada and 8 more countries
Ages 12–17
Dr George Medvedev · Sites in Canada
Ages 19–75
By country, each count listing its studies:
eptinezumab: first FDA approval 2020 (VYEPTI), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 892 is above the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Median enrollment 193 across the 21 interventional studies. Of the 15 that completed or were terminated, 8 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 21 have an industry lead sponsor. The 5 most frequent:
H. Lundbeck A/S is the lead sponsor of 224 studies on the registry; 9 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.
23 studies in Migraine Disorders by H. Lundbeck A/S: 3 open now, 3 under way, 3 of them phase 3. Of 20 finished, 9 (45%) have results posted.
Among the 23 studies in Migraine Disorders by H. Lundbeck A/S, this one is the 4th largest by enrollment, is one of 2 that started in 2020, is one of 11 in phase 3, and was the 9th registered.
H. Lundbeck A/S’s Migraine Disorders studies by the year they started, since 2012.
3 of the studies testing eptinezumab in Migraine Disorders that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04965675Phase 3H. Lundbeck A/SA Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine | 2027-03-26 |
| NCT07191145Phase 3Sunnybrook Health Sciences CentreEary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT) | 2027-06-30 |
| NCT05897320Phase 3H. Lundbeck A/SA Study of Eptinezumab in Pediatric Participants With Episodic Migraine | 2027-07-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 21 studies testing eptinezumab in Migraine Disorders, from their registry updates:
Among H. Lundbeck A/S’s 23 in Migraine Disorders:
This tab as a report to print or save as PDF → With an account.
Evaluation of eptinezumab in the prevention of migraine in participants with unsuccessful prior preventive treatments.
The total study duration from the screening visit to the completion visit is approximately 76 weeks and includes a screening period (28-30 days), a placebo-controlled treatment period (24 weeks) and a treatment extension period (48 weeks).
The participant will start treatment at the baseline visit and follow a 12-week dosing schedule with either eptinezumab (100 or 300 milligrams [mg]) or placebo by intraveneous (IV) infusion. Participants who were assigned to placebo in the placebo-controlled treatment period, will be randomly allocated to one of two treatment groups: eptinezumab 300 mg or eptinezumab 100 mg.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other in- and exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive placebo matching to eptinezumab by IV infusion, every 12 weeks starting from Baseline (Day 0) through Week 24.
Drug: Placebo
Participants will receive eptinezumab 100 mg by IV infusion, every 12 weeks starting from Baseline (Day 0) through Week 24.
Drug: Eptinezumab
Participants will receive eptinezumab 300 mg by IV infusion, every 12 weeks starting from Baseline (Day 0) through Week 24.
Drug: Eptinezumab
Eptinezumab, concentrate for solution for infusion 100 mg/milliliter (mL)
concentrate for solution for infusion, intravenously
Change From Baseline in the Number of Monthly Migraine Days (MMDs) Averaged Over Weeks 1 to 12
A migraine day was defined as any day the participant reported a headache that met criterion A, B, C, or D: Criterion A (all of the following criteria): lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity; and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion B: lasted ≥30 minutes and the participant had an aura with the headache. Criterion C: lasted ≥30 minutes and met ≥2 of the following criteria: lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity, and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion D: the participant took medication to treat the headache because he/she believed he/she was having a migraine.
Time frame: Baseline, Weeks 1 - 12
Percentage of Participants With ≥50% Reduction From Baseline in MMDs Averaged Over Weeks 1 to 12
A migraine day was defined as any day the participant reported a headache that met criterion A, B, C, or D: Criterion A (all of the following criteria): lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity; and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion B: lasted ≥30 minutes and the participant had an aura with the headache. Criterion C: lasted ≥30 minutes and met ≥2 of the following criteria: lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity, and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion D: the participant took medication to treat the headache because he/she believed he/she was having a migraine.
Time frame: Baseline to Weeks 1 - 12
Change From Baseline in the Number of MMDs Averaged Over Weeks 13 to 24
A migraine day was defined as any day the participant reported a headache that met criterion A, B, C, or D: Criterion A (all of the following criteria): lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity; and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion B: lasted ≥30 minutes and the participant had an aura with the headache. Criterion C: lasted ≥30 minutes and met ≥2 of the following criteria: lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity, and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion D: the participant took medication to treat the headache because he/she believed he/she was having a migraine.
Time frame: Baseline, Weeks 13 - 24
Percentage of Participants With ≥75% Reduction From Baseline in MMDs Averaged Over Weeks 1 to 12
A migraine day was defined as any day the participant reported a headache that met criterion A, B, C, or D: Criterion A (all of the following criteria): lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity; and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion B: lasted ≥30 minutes and the participant had an aura with the headache. Criterion C: lasted ≥30 minutes and met ≥2 of the following criteria: lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity, and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion D: the participant took medication to treat the headache because he/she believed he/she was having a migraine.
Time frame: Baseline to Weeks 1 - 12
Change From Baseline in the Headache Impact Test (HIT-6) Score at Week 12
The HIT-6 (version 1.0) is a Likert-type, self-reporting questionnaire designed to assess the impact of an occurring headache and its effect on the ability to function normally in daily life. The HIT-6 contains 6 questions, each item was rated from never to always with the following response scores: never = 6, rarely = 8, sometimes = 10, very often = 11, and always = 13. The total score for the HIT-6 was the sum of each response score ranging from 36 to 78. The life impact derived from the total score was described as followed: severe (≥60), substantial (56-59), some (50-55), little to none (≤49).
Time frame: Baseline, Week 12
Percentage of Participants With ≥50% Reduction From Baseline in MMDs Averaged Over Weeks 13 to 24
A migraine day was defined as any day the participant reported a headache that met criterion A, B, C, or D: Criterion A (all of the following criteria): lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity; and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion B: lasted ≥30 minutes and the participant had an aura with the headache. Criterion C: lasted ≥30 minutes and met ≥2 of the following criteria: lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity, and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion D: the participant took medication to treat the headache because he/she believed he/she was having a migraine.
Time frame: Baseline to Weeks 13 - 24
Percentage of Participants With ≥75% Reduction From Baseline in MMDs Averaged Over Weeks 13 to 24
A migraine day was defined as any day the participant reported a headache that met criterion A, B, C, or D: Criterion A (all of the following criteria): lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity; and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion B: lasted ≥30 minutes and the participant had an aura with the headache. Criterion C: lasted ≥30 minutes and met ≥2 of the following criteria: lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity, and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion D: the participant took medication to treat the headache because he/she believed he/she was having a migraine.
Time frame: Baseline to Weeks 13 - 24
Percentage of Participants With 100% Reduction From Baseline in MMDs Averaged Over Weeks 1 to 12
A migraine day was defined as any day the participant reported a headache that met criterion A, B, C, or D: Criterion A (all of the following criteria): lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity; and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion B: lasted ≥30 minutes and the participant had an aura with the headache. Criterion C: lasted ≥30 minutes and met ≥2 of the following criteria: lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity, and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion D: the participant took medication to treat the headache because he/she believed he/she was having a migraine.
Time frame: Baseline to Weeks 1 - 12
Percentage of Participants With ≥50% Reduction From Baseline in Monthly Headache Days (MHDs) Averaged Over Weeks 1 to 12
A headache day was defined as a day with a headache that lasted ≥30 minutes or met the definition of a migraine day (as defined in criterion A, B, C, or D above in outcome measure 1).
Time frame: Baseline to Weeks 1 - 12
Percentage of Participants With ≥75% Reduction From Baseline in Monthly Headache Days (MHDs) Averaged Over Weeks 1 to 12
A headache day was defined as a day with a headache that lasted ≥30 minutes or met the definition of a migraine day (as defined in criterion A, B, C, or D above in outcome measure 1).
Time frame: Baseline to Weeks 1 - 12
Percentage of Participants With 100% Reduction From Baseline in Monthly Headache Days (MHDs) Averaged Over Weeks 1 to 12
A headache day was defined as a day with a headache that lasted ≥30 minutes or met the definition of a migraine day (as defined in criterion A, B, C, or D above in outcome measure 1).
Time frame: Baseline to Weeks 1 - 12
Change From Baseline in the Number of MHDs Averaged Over Weeks 1 to 12
A headache day was defined as a day with a headache that lasted ≥30 minutes or met the definition of a migraine day (as defined in criterion A, B, C, or D above in outcome measure 1).
Time frame: Baseline, Weeks 1 - 12
Change From Baseline in the Percentage of Migraine Attacks With Severe Pain Intensity Averaged Over Weeks 1 to 12
A migraine attack was defined as a headache that occurred on a single day or lasted \>1 day and that met the criteria for a migraine day (as defined in criterion A, B, C, or D above in outcome measure 1).
Time frame: Baseline, Weeks 1 - 12
Change From Baseline in the Percentage of Headache Episodes With Severe Pain Intensity Averaged Over Weeks 1 to 12
A headache episode was defined as a headache lasted ≥30 minutes or that met the criteria for a migraine (as defined in criterion A, B, C, or D above in outcome measure 1).
Time frame: Baseline, Weeks 1 - 12
Change From Baseline in the Number of Monthly Days With Use of Acute Migraine Medication Averaged Over Weeks 1 to 12
In the evening eDiary, participants were asked each day to fill out whether they used any of the following medications during that day: Ergotamine, triptan, analgesic, opioid, or combination analgesic. A day where the participant answered that they took any of those in the evening eDiary was considered a day with use of acute migraine medication.
Time frame: Baseline, Weeks 1 - 12
Change From Baseline in the Number of Monthly Days With Use of Acute Migraine Medication Averaged Over Weeks 13 to 24
In the evening eDiary, participants were asked each day to fill out whether they used any of the following medications during that day: Ergotamine, triptan, analgesic, opioid, or combination analgesic. A day where the participant answered that they took any of those in the evening eDiary was considered a day with use of acute migraine medication.
Time frame: Baseline, Weeks 13- 24
Change From Baseline in the Number of MMDs With Use of Acute Medication Averaged Over Weeks 1 to 12
Number of MMDs with acute medication usage was derived using the answer to "Did you take any medications to treat this headache?" in the headache diary. The question was asked when a participant was ending a headache. Thus, a migraine day with acute medication usage was defined as a migraine day with the extra condition that this question was answered as "Yes".
Time frame: Baseline, Weeks 1 - 12
Change From Baseline in the Number of MMDs With Use of Acute Medication Averaged Over Weeks 13 to 24
Number of MMDs with acute medication usage was derived using the answer to "Did you take any medications to treat this headache?" in the headache diary. The question was asked when a participant was ending a headache. Thus, a migraine day with acute medication usage was defined as a migraine day with the extra condition that this question was answered as "Yes".
Time frame: Baseline, Weeks 13 - 24
Patient Global Impression of Change (PGIC) Score at Week 12
The PGIC is a single, participant-reported item reflecting the participant's impression of change in his/her disease status since the start of the study (that is, in relation to activity limitations, symptoms, emotions, and overall quality of life). Participants rated their impression of change in disease status on a 7-point scale (1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse) where a higher score indicated worsening. Score ranges from 1 (Very Much Improved) to 7 (Very Much Worse). Lower scores indicate better health status.
Time frame: Week 12
PGIC Score at Week 24
The PGIC is a single, participant-reported item reflecting the participant's impression of change in his/her disease status since the start of the study (that is, in relation to activity limitations, symptoms, emotions, and overall quality of life). Participants rated their impression of change in disease status on a 7-point scale (1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse) where a higher score indicated worsening. Score ranges from 1 (Very Much Improved) to 7 (Very Much Worse). Lower scores indicate better health status.
Time frame: Week 24
Change From Baseline in the Number of MMDs in Participants With Medication Overuse Headache (MOH) Averaged Over Weeks 1 to 12
Time frame: Baseline, Weeks 1 - 12
Percentage of Participants With Migraine on the Day After First Dosing
Time frame: Day 1
Most Bothersome Symptom (MBS) Score at Week 12
Participants were asked about their most bothersome symptom associated with their migraines during the Baseline Visit. Participants were asked to rate the improvement in this symptom from baseline on a 7-point scale (1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse) where a high score indicated worsening. Score ranges from 1 (Very Much Improved) to 7 (Very Much Worse). Lower scores indicate better health status. The MBS areas included: nausea, vomiting, sensitivity to light, sensitivity to sound, mental cloudiness, fatigue, pain with activity, mood changes, and other symptoms.
Time frame: Week 12
Change From Baseline in the HIT-6 Score at Week 24
The HIT-6 (version 1.0) is a Likert-type, self-reporting questionnaire designed to assess the impact of an occurring headache and its effect on the ability to function normally in daily life. The HIT-6 contains 6 questions, each item was rated from never to always with the following response scores: never = 6, rarely = 8, sometimes = 10, very often = 11, and always = 13. The total score for the HIT-6 was the sum of each response score ranging from 36 to 78. The life impact derived from the total score was described as followed: severe (≥60), substantial (56-59), some (50-55), little to none (≤49).
Time frame: Baseline, Week 24
Change From Baseline in the Migraine-Specific Quality of Life (MSQ) Subscores (Role Function-Restrictive, Role Function-Preventive, Emotional Function) at Week 12
The MSQ is a participant-reported outcome designed to assess the quality of life in participants with migraine. It consists of 14 items covering 3 domains: role function restrictive (7 items); role function preventive (4 items); and emotional function (3 items). Each item was scored on a 6-point scale ranging from 1 (none of the time) to 6 (all of the time). Raw domain scores were summed and transformed to a 0- to 100-point scale. Higher scores indicated better quality of life.
Time frame: Baseline, Week 12
Change From Baseline in the Health-Related Quality of Life (EQ-5D-5L) Visual Analog Scale (VAS) Score at Week 12
The EQ-5D-5L is a participant-reported assessment designed to measure the participant's well-being. It consists of 5 descriptive items (mobility, self-care, usual activities, pain/discomfort, and depression/anxiety) and a VAS of the overall health state. Each descriptive item was rated on a 5-point index ranging from 1 (no problems) to 5 (extreme problems). The VAS ranged from 0 (worst imaginable health state) to 100 (best imaginable health state).
Time frame: Baseline, Week 12
Change From Baseline in the MSQ Subscores (Role Function-Restrictive, Role Function-Preventive, Emotional Function) at Week 24
The MSQ is a participant-reported outcome designed to assess the quality of life in participants with migraine. It consists of 14 items covering 3 domains: role function restrictive (7 items); role function preventive (4 items); and emotional function (3 items). Each item was scored on a 6-point scale ranging from 1 (none of the time) to 6 (all of the time). Raw domain scores were summed and transformed to a 0- to 100-point scale. Higher scores indicated better quality of life.
Time frame: Baseline, Week 24
Change From Baseline in the Health-Related Quality of Life (EQ-5D-5L) VAS Score at Week 24
The EQ-5D-5L is a participant-reported assessment designed to measure the participant's well-being. It consists of 5 descriptive items (mobility, self-care, usual activities, pain/discomfort, and depression/anxiety) and a VAS of the overall health state. Each descriptive item was rated on a 5-point index ranging from 1 (no problems) to 5 (extreme problems). The VAS ranged from 0 (worst imaginable health state) to 100 (best imaginable health state).
Time frame: Baseline, Week 24
Change From Baseline in the Work Productivity and Activity Impairment (WPAI) Questionnaire Subscores (Absenteeism, Presenteeism, Work Productivity Loss, Activity Impairment) at Week 12
The WPAI Questionnaire is a participant-reported instrument developed to measure the impact on work productivity and regular activities attributable to a specific health problem (migraine). Recall period is the past 7 days. It contains 6 items that measure: 1) employment status, 2) hours missed from work due to the specific health problem, 3) hours missed from work for other reasons, 4) hours actually worked, 5) degree health affected productivity while working, and 6) degree health affected productivity in regular unpaid activities. Four scores were calculated from the responses to these 6 items: absenteeism, presenteeism, work productivity loss, and activity impairment. Scores were calculated as impairment percentages (0-100%), with higher numbers indicating greater impairment and less productivity, i.e, worse outcomes.
Time frame: Baseline, Week 12
Change From Baseline in the WPAI Questionnaire Subscores (Absenteeism, Presenteeism, Work Productivity Loss, Activity Impairment) at Week 24
The WPAI Questionnaire is a participant-reported instrument developed to measure the impact on work productivity and regular activities attributable to a specific health problem (migraine). Recall period is the past 7 days. It contains 6 items that measure: 1) employment status, 2) hours missed from work due to the specific health problem, 3) hours missed from work for other reasons, 4) hours actually worked, 5) degree health affected productivity while working, and 6) degree health affected productivity in regular unpaid activities. Four scores were calculated from the responses to these 6 items: absenteeism, presenteeism, work productivity loss, and activity impairment. Scores were calculated as impairment percentages (0-100%), with higher numbers indicating greater impairment and less productivity, i.e, worse outcomes.
Time frame: Baseline, Week 24
Percentage of Participants With ≥5-Point Reduction From Baseline to Week 12 in HIT-6 Score
The HIT-6 (version 1.0) is a Likert-type, self-reporting questionnaire designed to assess the impact of an occurring headache and its effect on the ability to function normally in daily life. The HIT-6 contains 6 questions, each item was rated from never to always with the following response scores: never = 6, rarely = 8, sometimes = 10, very often = 11, and always = 13. The total score for the HIT-6 was the sum of each response score ranging from 36 to 78. The life impact derived from the total score was described as followed: severe (≥60), substantial (56-59), some (50-55), little to none (≤49).
Time frame: Baseline to Week 12
Percentage of Participants With ≥5-Point Reduction From Baseline to Week 24 in HIT-6 Score
The HIT-6 (version 1.0) is a Likert-type, self-reporting questionnaire designed to assess the impact of an occurring headache and its effect on the ability to function normally in daily life. The HIT-6 contains 6 questions, each item was rated from never to always with the following response scores: never = 6, rarely = 8, sometimes = 10, very often = 11, and always = 13. The total score for the HIT-6 was the sum of each response score ranging from 36 to 78. The life impact derived from the total score was described as followed: severe (≥60), substantial (56-59), some (50-55), little to none (≤49).
Time frame: Baseline to Week 24
Health Care Resource Utilization (HCRU): Visits to a Family Doctor/General Practitioner
Number of participants who visited to a family doctor/general practitioner has been reported.
Time frame: Week 12
HCRU: Visits to a Specialist
Number of participants who visited to a specialist has been reported.
Time frame: Week 12
HCRU: Number of Emergency Department Visits Due to Your Migraine
Number of participants who visited to emergency department due to your migraine has been reported.
Time frame: Week 12
HCRU: Number of Hospital Admissions Due to Migraine
Number of participants who admitted in the hospital due to migraine has been reported.
Time frame: Week 12
HCRU: Total Number of Overnight Hospital Stays Due to Migraine
Number of participants who had total number of overnight hospital stays due to migraine has been reported.
Time frame: Week 12
Change From Baseline in the Number of MMDs Averaged Over Weeks 25 to 36, 37 to 48, 49 to 60, and 61 to 72
A migraine day was defined as any day the participant reported a headache that met criterion A, B, C, or D: Criterion A (all of the following criteria): lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity; and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion B: lasted ≥30 minutes and the participant had an aura with the headache. Criterion C: lasted ≥30 minutes and met ≥2 of the following criteria: lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity, and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion D: the participant took medication to treat the headache because he/she believed he/she was having a migraine.
Time frame: Baseline, Weeks 25 - 36, 37 - 48, 49 - 60, and 61 - 72
Percentage of Participants With ≥50% Reduction From Baseline in MMDs Averaged Over Weeks 25 to 36, 37 to 48, 49 to 60, and 61 to 72
A migraine day was defined as any day the participant reported a headache that met criterion A, B, C, or D: Criterion A (all of the following criteria): lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity; and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion B: lasted ≥30 minutes and the participant had an aura with the headache. Criterion C: lasted ≥30 minutes and met ≥2 of the following criteria: lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity, and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion D: the participant took medication to treat the headache because he/she believed he/she was having a migraine.
Time frame: Baseline to Weeks 25 - 36, 37 - 48, 49 - 60, and 61 - 72
Percentage of Participants With ≥75% Reduction From Baseline in MMDs Averaged Over Weeks 25 to 36, 37 to 48, 49 to 60, and 61 to 72
A migraine day was defined as any day the participant reported a headache that met criterion A, B, C, or D: Criterion A (all of the following criteria): lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity; and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion B: lasted ≥30 minutes and the participant had an aura with the headache. Criterion C: lasted ≥30 minutes and met ≥2 of the following criteria: lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity, and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion D: the participant took medication to treat the headache because he/she believed he/she was having a migraine.
Time frame: Baseline to Weeks 25 - 36, 37 - 48, 49 - 60, and 61 - 72
Change From Baseline in HIT-6 Score at Weeks 36, 48, 60, and 72
The HIT-6 (version 1.0) is a Likert-type, self-reporting questionnaire designed to assess the impact of an occurring headache and its effect on the ability to function normally in daily life. The HIT-6 contains 6 questions, each item was rated from never to always with the following response scores: never = 6, rarely = 8, sometimes = 10, very often = 11, and always = 13. The total score for the HIT-6 was the sum of each response score ranging from 36 to 78. The life impact derived from the total score was described as followed: severe (≥60), substantial (56-59), some (50-55), little to none (≤49).
Time frame: Baseline, Weeks 36, 48, 60, and 72
This study included 2 periods: Placebo-controlled Period - 24-week double-blind treatment period with placebo or eptinezumab and Extension Period - 48-week dose-blinded period with eptinezumab after completion of the Placebo-controlled Period.
| Milestone | Placebo | Eptinezumab 100 mg | Eptinezumab 300 mg |
|---|---|---|---|
| Started | 299 | 299 | 294 |
| Received at least 1 dose of study drug | 298 | 299 | 294 |
| Completed | 293 | 288 | 284 |
| Not completed | 6 | 11 | 10 |
| Withdrew: Adverse event | 1 | 1 | 6 |
| Withdrew: Lack of efficacy | 1 | 3 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 5 | 2 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
| Withdrew: Other than specified | 2 | 0 | 1 |
| Withdrew: Randomized but not treated | 1 | 0 | 0 |
| Milestone | Placebo | Eptinezumab 100 mg | Eptinezumab 300 mg |
|---|---|---|---|
| Started | 0 | 433 | 432 |
| Received at least 1 dose of study drug | 0 | 433 | 432 |
| Completed | 0 | 392 | 390 |
| Not completed | 0 | 41 | 42 |
| Withdrew: Adverse event | 0 | 2 | 9 |
| Withdrew: Lack of efficacy | 0 | 13 | 13 |
| Withdrew: Withdrawal by subject | 0 | 21 | 14 |
| Withdrew: Non-compliance with study drug | 0 | 0 | 2 |
| Withdrew: Protocol violation | 0 | 0 | 2 |
| Withdrew: Other than specified | 0 | 5 | 2 |
A migraine day was defined as any day the participant reported a headache that met criterion A, B, C, or D: Criterion A (all of the following criteria): lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity; and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion B: lasted ≥30 minutes and the participant had an aura with the headache. Criterion C: lasted ≥30 minutes and met ≥2 of the following criteria: lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity, and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion D: the participant took medication to treat the headache because he/she believed he/she was having a migraine.
| days/month | Placebo | Eptinezumab 100 mg | Eptinezumab 300 mg |
|---|---|---|---|
| Change From Baseline in the Number of Monthly Migraine Days (MMDs) Averaged Over Weeks 1 to 12 | -2.1 ± 0.38 | -4.8 ± 0.37 | -5.3 ± 0.37 |
A migraine day was defined as any day the participant reported a headache that met criterion A, B, C, or D: Criterion A (all of the following criteria): lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity; and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion B: lasted ≥30 minutes and the participant had an aura with the headache. Criterion C: lasted ≥30 minutes and met ≥2 of the following criteria: lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity, and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion D: the participant took medication to treat the headache because he/she believed he/she was having a migraine.
| percentage of participants | Placebo | Eptinezumab 100 mg | Eptinezumab 300 mg |
|---|---|---|---|
| Percentage of Participants With ≥50% Reduction From Baseline in MMDs Averaged Over Weeks 1 to 12 | 13.1 | 42.1 | 49.5 |
A migraine day was defined as any day the participant reported a headache that met criterion A, B, C, or D: Criterion A (all of the following criteria): lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity; and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion B: lasted ≥30 minutes and the participant had an aura with the headache. Criterion C: lasted ≥30 minutes and met ≥2 of the following criteria: lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity, and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion D: the participant took medication to treat the headache because he/she believed he/she was having a migraine.
| days/month | Placebo | Eptinezumab 100 mg | Eptinezumab 300 mg |
|---|---|---|---|
| Change From Baseline in the Number of MMDs Averaged Over Weeks 13 to 24 | -2.4 ± 0.39 | -5.4 ± 0.39 | -6.1 ± 0.39 |
A migraine day was defined as any day the participant reported a headache that met criterion A, B, C, or D: Criterion A (all of the following criteria): lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity; and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion B: lasted ≥30 minutes and the participant had an aura with the headache. Criterion C: lasted ≥30 minutes and met ≥2 of the following criteria: lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity, and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion D: the participant took medication to treat the headache because he/she believed he/she was having a migraine.
| percentage of participants | Placebo | Eptinezumab 100 mg | Eptinezumab 300 mg |
|---|---|---|---|
| Percentage of Participants With ≥75% Reduction From Baseline in MMDs Averaged Over Weeks 1 to 12 | 2.0 | 15.7 | 18.8 |
The HIT-6 (version 1.0) is a Likert-type, self-reporting questionnaire designed to assess the impact of an occurring headache and its effect on the ability to function normally in daily life. The HIT-6 contains 6 questions, each item was rated from never to always with the following response scores: never = 6, rarely = 8, sometimes = 10, very often = 11, and always = 13. The total score for the HIT-6 was the sum of each response score ranging from 36 to 78. The life impact derived from the total score was described as followed: severe (≥60), substantial (56-59), some (50-55), little to none (≤49).
| units on a scale | Placebo | Eptinezumab 100 mg | Eptinezumab 300 mg |
|---|---|---|---|
| Change From Baseline in the Headache Impact Test (HIT-6) Score at Week 12 | -3.1 ± 0.61 | -6.9 ± 0.61 | -8.5 ± 0.60 |
A migraine day was defined as any day the participant reported a headache that met criterion A, B, C, or D: Criterion A (all of the following criteria): lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity; and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion B: lasted ≥30 minutes and the participant had an aura with the headache. Criterion C: lasted ≥30 minutes and met ≥2 of the following criteria: lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity, and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion D: the participant took medication to treat the headache because he/she believed he/she was having a migraine.
| percentage of participants | Placebo | Eptinezumab 100 mg | Eptinezumab 300 mg |
|---|---|---|---|
| Percentage of Participants With ≥50% Reduction From Baseline in MMDs Averaged Over Weeks 13 to 24 | 23.7 | 52.3 | 59.1 |
A migraine day was defined as any day the participant reported a headache that met criterion A, B, C, or D: Criterion A (all of the following criteria): lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity; and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion B: lasted ≥30 minutes and the participant had an aura with the headache. Criterion C: lasted ≥30 minutes and met ≥2 of the following criteria: lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity, and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion D: the participant took medication to treat the headache because he/she believed he/she was having a migraine.
| percentage of participants | Placebo | Eptinezumab 100 mg | Eptinezumab 300 mg |
|---|---|---|---|
| Percentage of Participants With ≥75% Reduction From Baseline in MMDs Averaged Over Weeks 13 to 24 | 6.8 | 21.3 | 27.6 |
A migraine day was defined as any day the participant reported a headache that met criterion A, B, C, or D: Criterion A (all of the following criteria): lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity; and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion B: lasted ≥30 minutes and the participant had an aura with the headache. Criterion C: lasted ≥30 minutes and met ≥2 of the following criteria: lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity, and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion D: the participant took medication to treat the headache because he/she believed he/she was having a migraine.
| percentage of participants | Placebo | Eptinezumab 100 mg | Eptinezumab 300 mg |
|---|---|---|---|
| Percentage of Participants With 100% Reduction From Baseline in MMDs Averaged Over Weeks 1 to 12 | 1.1 | 5.9 | 7.7 |
A headache day was defined as a day with a headache that lasted ≥30 minutes or met the definition of a migraine day (as defined in criterion A, B, C, or D above in outcome measure 1).
| percentage of participants | Placebo | Eptinezumab 100 mg | Eptinezumab 300 mg |
|---|---|---|---|
| Percentage of Participants With ≥50% Reduction From Baseline in Monthly Headache Days (MHDs) Averaged Over Weeks 1 to 12 | 12.8 | 39.5 | 45.7 |
A headache day was defined as a day with a headache that lasted ≥30 minutes or met the definition of a migraine day (as defined in criterion A, B, C, or D above in outcome measure 1).
| percentage of participants | Placebo | Eptinezumab 100 mg | Eptinezumab 300 mg |
|---|---|---|---|
| Percentage of Participants With ≥75% Reduction From Baseline in Monthly Headache Days (MHDs) Averaged Over Weeks 1 to 12 | 2.3 | 15.1 | 16.4 |
A headache day was defined as a day with a headache that lasted ≥30 minutes or met the definition of a migraine day (as defined in criterion A, B, C, or D above in outcome measure 1).
| percentage of participants | Placebo | Eptinezumab 100 mg | Eptinezumab 300 mg |
|---|---|---|---|
| Percentage of Participants With 100% Reduction From Baseline in Monthly Headache Days (MHDs) Averaged Over Weeks 1 to 12 | 1.1 | 4.1 | 5.3 |
A headache day was defined as a day with a headache that lasted ≥30 minutes or met the definition of a migraine day (as defined in criterion A, B, C, or D above in outcome measure 1).
| days/month | Placebo | Eptinezumab 100 mg | Eptinezumab 300 mg |
|---|---|---|---|
| Change From Baseline in the Number of MHDs Averaged Over Weeks 1 to 12 | -2.1 ± 0.38 | -4.6 ± 0.37 | -5.1 ± 0.37 |
A migraine attack was defined as a headache that occurred on a single day or lasted \>1 day and that met the criteria for a migraine day (as defined in criterion A, B, C, or D above in outcome measure 1).
| percentage of migraine attacks | Placebo | Eptinezumab 100 mg | Eptinezumab 300 mg |
|---|---|---|---|
| Change From Baseline in the Percentage of Migraine Attacks With Severe Pain Intensity Averaged Over Weeks 1 to 12 | -10.2 ± 1.91 | -17.9 ± 1.87 | -21.3 ± 1.87 |
A headache episode was defined as a headache lasted ≥30 minutes or that met the criteria for a migraine (as defined in criterion A, B, C, or D above in outcome measure 1).
| percentage of headache episodes | Placebo | Eptinezumab 100 mg | Eptinezumab 300 mg |
|---|---|---|---|
| Change From Baseline in the Percentage of Headache Episodes With Severe Pain Intensity Averaged Over Weeks 1 to 12 | -8.8 ± 1.85 | -16.2 ± 1.81 | -19.5 ± 1.81 |
In the evening eDiary, participants were asked each day to fill out whether they used any of the following medications during that day: Ergotamine, triptan, analgesic, opioid, or combination analgesic. A day where the participant answered that they took any of those in the evening eDiary was considered a day with use of acute migraine medication.
| days/month | Placebo | Eptinezumab 100 mg | Eptinezumab 300 mg |
|---|---|---|---|
| Change From Baseline in the Number of Monthly Days With Use of Acute Migraine Medication Averaged Over Weeks 1 to 12 | -1.6 ± 0.34 | -4.1 ± 0.33 | -4.6 ± 0.34 |
In the evening eDiary, participants were asked each day to fill out whether they used any of the following medications during that day: Ergotamine, triptan, analgesic, opioid, or combination analgesic. A day where the participant answered that they took any of those in the evening eDiary was considered a day with use of acute migraine medication.
| days/month | Placebo | Eptinezumab 100 mg | Eptinezumab 300 mg |
|---|---|---|---|
| Change From Baseline in the Number of Monthly Days With Use of Acute Migraine Medication Averaged Over Weeks 13 to 24 | -1.7 ± 0.36 | -4.6 ± 0.36 | -5.2 ± 0.36 |
Number of MMDs with acute medication usage was derived using the answer to "Did you take any medications to treat this headache?" in the headache diary. The question was asked when a participant was ending a headache. Thus, a migraine day with acute medication usage was defined as a migraine day with the extra condition that this question was answered as "Yes".
| days/month | Placebo | Eptinezumab 100 mg | Eptinezumab 300 mg |
|---|---|---|---|
| Change From Baseline in the Number of MMDs With Use of Acute Medication Averaged Over Weeks 1 to 12 | -2.0 ± 0.36 | -4.6 ± 0.36 | -5.2 ± 0.36 |
Number of MMDs with acute medication usage was derived using the answer to "Did you take any medications to treat this headache?" in the headache diary. The question was asked when a participant was ending a headache. Thus, a migraine day with acute medication usage was defined as a migraine day with the extra condition that this question was answered as "Yes".
| days/month | Placebo | Eptinezumab 100 mg | Eptinezumab 300 mg |
|---|---|---|---|
| Change From Baseline in the Number of MMDs With Use of Acute Medication Averaged Over Weeks 13 to 24 | -2.1 ± 0.39 | -4.9 ± 0.39 | -5.8 ± 0.38 |
The PGIC is a single, participant-reported item reflecting the participant's impression of change in his/her disease status since the start of the study (that is, in relation to activity limitations, symptoms, emotions, and overall quality of life). Participants rated their impression of change in disease status on a 7-point scale (1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse) where a higher score indicated worsening. Score ranges from 1 (Very Much Improved) to 7 (Very Much Worse). Lower scores indicate better health status.
| units on a scale | Placebo | Eptinezumab 100 mg | Eptinezumab 300 mg |
|---|---|---|---|
| Patient Global Impression of Change (PGIC) Score at Week 12 | 3.6 ± 0.09 | 2.6 ± 0.09 | 2.5 ± 0.09 |
The PGIC is a single, participant-reported item reflecting the participant's impression of change in his/her disease status since the start of the study (that is, in relation to activity limitations, symptoms, emotions, and overall quality of life). Participants rated their impression of change in disease status on a 7-point scale (1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse) where a higher score indicated worsening. Score ranges from 1 (Very Much Improved) to 7 (Very Much Worse). Lower scores indicate better health status.
| units on a scale | Placebo | Eptinezumab 100 mg | Eptinezumab 300 mg |
|---|---|---|---|
| PGIC Score at Week 24 | 3.5 ± 0.09 | 2.5 ± 0.09 | 2.4 ± 0.09 |
| days/month | Placebo | Eptinezumab 100 mg | Eptinezumab 300 mg |
|---|---|---|---|
| Change From Baseline in the Number of MMDs in Participants With Medication Overuse Headache (MOH) Averaged Over Weeks 1 to 12 | -2.3 ± 1.12 | -5.6 ± 1.07 | -7.3 ± 1.18 |
| percentage of participants | Placebo | Eptinezumab 100 mg | Eptinezumab 300 mg |
|---|---|---|---|
| Percentage of Participants With Migraine on the Day After First Dosing | 43.7 | 27.2 | 24.4 |
Participants were asked about their most bothersome symptom associated with their migraines during the Baseline Visit. Participants were asked to rate the improvement in this symptom from baseline on a 7-point scale (1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse) where a high score indicated worsening. Score ranges from 1 (Very Much Improved) to 7 (Very Much Worse). Lower scores indicate better health status. The MBS areas included: nausea, vomiting, sensitivity to light, sensitivity to sound, mental cloudiness, fatigue, pain with activity, mood changes, and other symptoms.
| units on a scale | Placebo | Eptinezumab 100 mg | Eptinezumab 300 mg |
|---|---|---|---|
| Most Bothersome Symptom (MBS) Score at Week 12 | 3.7 ± 0.09 | 2.8 ± 0.09 | 2.7 ± 0.09 |
The HIT-6 (version 1.0) is a Likert-type, self-reporting questionnaire designed to assess the impact of an occurring headache and its effect on the ability to function normally in daily life. The HIT-6 contains 6 questions, each item was rated from never to always with the following response scores: never = 6, rarely = 8, sometimes = 10, very often = 11, and always = 13. The total score for the HIT-6 was the sum of each response score ranging from 36 to 78. The life impact derived from the total score was described as followed: severe (≥60), substantial (56-59), some (50-55), little to none (≤49).
| units on a scale | Placebo | Eptinezumab 100 mg | Eptinezumab 300 mg |
|---|---|---|---|
| Change From Baseline in the HIT-6 Score at Week 24 | -3.9 ± 0.63 | -8.9 ± 0.63 | -9.9 ± 0.62 |
The MSQ is a participant-reported outcome designed to assess the quality of life in participants with migraine. It consists of 14 items covering 3 domains: role function restrictive (7 items); role function preventive (4 items); and emotional function (3 items). Each item was scored on a 6-point scale ranging from 1 (none of the time) to 6 (all of the time). Raw domain scores were summed and transformed to a 0- to 100-point scale. Higher scores indicated better quality of life.
| units on a scale | Placebo | Eptinezumab 100 mg | Eptinezumab 300 mg |
|---|---|---|---|
| MSQ Role Function-Restrictive | 13.7 ± 1.75 | 25.0 ± 1.75 | 28.7 ± 1.72 |
| MSQ Role Function-Preventive | 11.6 ± 1.63 | 22.7 ± 1.64 | 25.0 ± 1.61 |
| MSQ Emotional Function | 9.6 ± 1.83 | 20.6 ± 1.84 | 23.1 ± 1.80 |
The EQ-5D-5L is a participant-reported assessment designed to measure the participant's well-being. It consists of 5 descriptive items (mobility, self-care, usual activities, pain/discomfort, and depression/anxiety) and a VAS of the overall health state. Each descriptive item was rated on a 5-point index ranging from 1 (no problems) to 5 (extreme problems). The VAS ranged from 0 (worst imaginable health state) to 100 (best imaginable health state).
| units on a scale | Placebo | Eptinezumab 100 mg | Eptinezumab 300 mg |
|---|---|---|---|
| Change From Baseline in the Health-Related Quality of Life (EQ-5D-5L) Visual Analog Scale (VAS) Score at Week 12 | -3.1 ± 1.39 | 2.0 ± 1.40 | 4.4 ± 1.38 |
The MSQ is a participant-reported outcome designed to assess the quality of life in participants with migraine. It consists of 14 items covering 3 domains: role function restrictive (7 items); role function preventive (4 items); and emotional function (3 items). Each item was scored on a 6-point scale ranging from 1 (none of the time) to 6 (all of the time). Raw domain scores were summed and transformed to a 0- to 100-point scale. Higher scores indicated better quality of life.
| units on a scale | Placebo | Eptinezumab 100 mg | Eptinezumab 300 mg |
|---|---|---|---|
| MSQ Role Function-Restrictive | 15.0 ± 1.76 | 30.1 ± 1.78 | 30.0 ± 1.73 |
| MSQ Role Function-Preventive | 13.1 ± 1.63 | 25.7 ± 1.65 | 26.3 ± 1.61 |
| MSQ Emotional Function | 9.9 ± 1.84 | 24.1 ± 1.86 | 24.1 ± 1.81 |
The EQ-5D-5L is a participant-reported assessment designed to measure the participant's well-being. It consists of 5 descriptive items (mobility, self-care, usual activities, pain/discomfort, and depression/anxiety) and a VAS of the overall health state. Each descriptive item was rated on a 5-point index ranging from 1 (no problems) to 5 (extreme problems). The VAS ranged from 0 (worst imaginable health state) to 100 (best imaginable health state).
| units on a scale | Placebo | Eptinezumab 100 mg | Eptinezumab 300 mg |
|---|---|---|---|
| Change From Baseline in the Health-Related Quality of Life (EQ-5D-5L) VAS Score at Week 24 | -2.8 ± 1.38 | 2.0 ± 1.40 | 5.2 ± 1.37 |
The WPAI Questionnaire is a participant-reported instrument developed to measure the impact on work productivity and regular activities attributable to a specific health problem (migraine). Recall period is the past 7 days. It contains 6 items that measure: 1) employment status, 2) hours missed from work due to the specific health problem, 3) hours missed from work for other reasons, 4) hours actually worked, 5) degree health affected productivity while working, and 6) degree health affected productivity in regular unpaid activities. Four scores were calculated from the responses to these 6 items: absenteeism, presenteeism, work productivity loss, and activity impairment. Scores were calculated as impairment percentages (0-100%), with higher numbers indicating greater impairment and less productivity, i.e, worse outcomes.
| units on a scale | Placebo | Eptinezumab 100 mg | Eptinezumab 300 mg |
|---|---|---|---|
| Absenteeism | -0.1 ± 1.49 | -5.8 ± 1.53 | -3.8 ± 1.50 |
| Presenteeism | -9.9 ± 2.42 | -19.0 ± 2.46 | -23.3 ± 2.40 |
| Work productivity loss | -9.7 ± 2.56 | -19.5 ± 2.61 | -24.0 ± 2.54 |
| Activity impairment | -11.2 ± 2.07 | -21.3 ± 2.07 | -23.8 ± 2.05 |
The WPAI Questionnaire is a participant-reported instrument developed to measure the impact on work productivity and regular activities attributable to a specific health problem (migraine). Recall period is the past 7 days. It contains 6 items that measure: 1) employment status, 2) hours missed from work due to the specific health problem, 3) hours missed from work for other reasons, 4) hours actually worked, 5) degree health affected productivity while working, and 6) degree health affected productivity in regular unpaid activities. Four scores were calculated from the responses to these 6 items: absenteeism, presenteeism, work productivity loss, and activity impairment. Scores were calculated as impairment percentages (0-100%), with higher numbers indicating greater impairment and less productivity, i.e, worse outcomes.
| units on a scale | Placebo | Eptinezumab 100 mg | Eptinezumab 300 mg |
|---|---|---|---|
| Absenteeism | -0.7 ± 1.46 | -5.2 ± 1.53 | -5.4 ± 1.47 |
| Presenteeism | -7.5 ± 2.49 | -22.2 ± 2.59 | -19.3 ± 2.46 |
| Work productivity loss | -7.2 ± 2.62 | -22.6 ± 2.73 | -20.2 ± 2.60 |
| Activity impairment | -10.1 ± 2.07 | -24.7 ± 2.09 | -22.6 ± 2.04 |
The HIT-6 (version 1.0) is a Likert-type, self-reporting questionnaire designed to assess the impact of an occurring headache and its effect on the ability to function normally in daily life. The HIT-6 contains 6 questions, each item was rated from never to always with the following response scores: never = 6, rarely = 8, sometimes = 10, very often = 11, and always = 13. The total score for the HIT-6 was the sum of each response score ranging from 36 to 78. The life impact derived from the total score was described as followed: severe (≥60), substantial (56-59), some (50-55), little to none (≤49).
| percentage of participants | Placebo | Eptinezumab 100 mg | Eptinezumab 300 mg |
|---|---|---|---|
| Percentage of Participants With ≥5-Point Reduction From Baseline to Week 12 in HIT-6 Score | 39.9 | 62.1 | 62.0 |
The HIT-6 (version 1.0) is a Likert-type, self-reporting questionnaire designed to assess the impact of an occurring headache and its effect on the ability to function normally in daily life. The HIT-6 contains 6 questions, each item was rated from never to always with the following response scores: never = 6, rarely = 8, sometimes = 10, very often = 11, and always = 13. The total score for the HIT-6 was the sum of each response score ranging from 36 to 78. The life impact derived from the total score was described as followed: severe (≥60), substantial (56-59), some (50-55), little to none (≤49).
| percentage of participants | Placebo | Eptinezumab 100 mg | Eptinezumab 300 mg |
|---|---|---|---|
| Percentage of Participants With ≥5-Point Reduction From Baseline to Week 24 in HIT-6 Score | 46.2 | 72.1 | 71.6 |
Number of participants who visited to a family doctor/general practitioner has been reported.
| Participants | Placebo | Eptinezumab 100 mg | Eptinezumab 300 mg |
|---|---|---|---|
| 0 Visit | 244 | 259 | 256 |
| 1 Visit | 35 | 22 | 22 |
| 2 Visits | 6 | 5 | 6 |
| 3 Visits | 7 | 2 | 3 |
| 4 Visits | 1 | 1 | 1 |
| 5 Visits | 1 | 2 | 1 |
| 6 Visits | 2 | 0 | 0 |
| 8 Visits | 1 | 0 | 0 |
Number of participants who visited to a specialist has been reported.
| Participants | Placebo | Eptinezumab 100 mg | Eptinezumab 300 mg |
|---|---|---|---|
| 0 Visit | 249 | 256 | 257 |
| 1 Visit | 33 | 31 | 24 |
| 2 Visits | 2 | 2 | 4 |
| 3 Visits | 7 | 2 | 4 |
| 5 Visits | 1 | 0 | 0 |
| 6 Visits | 4 | 0 | 0 |
| 8 Visits | 1 | 0 | 0 |
Number of participants who visited to emergency department due to your migraine has been reported.
| Participants | Placebo | Eptinezumab 100 mg | Eptinezumab 300 mg |
|---|---|---|---|
| 0 Visit | 289 | 289 | 285 |
| 1 Visit | 6 | 1 | 3 |
| 2 Visits | 0 | 1 | 1 |
| 3 Visits | 1 | 0 | 0 |
| 8 Visits | 1 | 0 | 0 |
Number of participants who admitted in the hospital due to migraine has been reported.
| Participants | Placebo | Eptinezumab 100 mg | Eptinezumab 300 mg |
|---|---|---|---|
| 0 Visit | 295 | 289 | 287 |
| 1 Visit | 1 | 1 | 2 |
| 2 Visits | 0 | 1 | 0 |
| 4 Visits | 1 | 0 | 0 |
Number of participants who had total number of overnight hospital stays due to migraine has been reported.
| Participants | Placebo | Eptinezumab 100 mg | Eptinezumab 300 mg |
|---|---|---|---|
| 0 Visit | 295 | 290 | 289 |
| 1 Visit | 1 | 0 | 0 |
| 3 Visits | 1 | 1 | 0 |
A migraine day was defined as any day the participant reported a headache that met criterion A, B, C, or D: Criterion A (all of the following criteria): lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity; and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion B: lasted ≥30 minutes and the participant had an aura with the headache. Criterion C: lasted ≥30 minutes and met ≥2 of the following criteria: lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity, and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion D: the participant took medication to treat the headache because he/she believed he/she was having a migraine.
| days/month | Placebo to Eptinezumab 100 mg | Placebo to Eptinezumab 300 mg | Eptinezumab 100 mg to Eptinezumab 100 mg | Eptinezumab 300 mg to Eptinezumab 300 mg |
|---|---|---|---|---|
| Change at Weeks 25-36 | -4.7 ± 0.49 | -6.1 ± 0.49 | -5.8 ± 0.39 | -5.9 ± 0.39 |
| Change at Weeks 37-48 | -5.0 ± 0.50 | -6.0 ± 0.50 | -5.8 ± 0.40 | -6.0 ± 0.40 |
| Change at Weeks 49-60 | -5.6 ± 0.51 | -6.6 ± 0.51 | -5.8 ± 0.41 | -6.0 ± 0.41 |
| Change at Weeks 61-72 | -5.9 ± 0.51 | -6.8 ± 0.51 | -6.6 ± 0.41 | -6.5 ± 0.41 |
A migraine day was defined as any day the participant reported a headache that met criterion A, B, C, or D: Criterion A (all of the following criteria): lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity; and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion B: lasted ≥30 minutes and the participant had an aura with the headache. Criterion C: lasted ≥30 minutes and met ≥2 of the following criteria: lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity, and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion D: the participant took medication to treat the headache because he/she believed he/she was having a migraine.
| percentage of participants | Placebo to Eptinezumab 100 mg | Placebo to Eptinezumab 300 mg | Eptinezumab 100 mg to Eptinezumab 100 mg | Eptinezumab 300 mg to Eptinezumab 300 mg |
|---|---|---|---|---|
| Weeks 25-36 | 48.6 | 63.0 | 59.6 | 61.0 |
| Weeks 37-48 | 49.3 | 60.3 | 60.6 | 61.9 |
| Weeks 49-60 | 59.7 | 68.6 | 62.6 | 62.3 |
| Weeks 61-72 | 63.5 | 69.9 | 68.3 | 65.9 |
A migraine day was defined as any day the participant reported a headache that met criterion A, B, C, or D: Criterion A (all of the following criteria): lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity; and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion B: lasted ≥30 minutes and the participant had an aura with the headache. Criterion C: lasted ≥30 minutes and met ≥2 of the following criteria: lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity, and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion D: the participant took medication to treat the headache because he/she believed he/she was having a migraine.
| percentage of participants | Placebo to Eptinezumab 100 mg | Placebo to Eptinezumab 300 mg | Eptinezumab 100 mg to Eptinezumab 100 mg | Eptinezumab 300 mg to Eptinezumab 300 mg |
|---|---|---|---|---|
| Weeks 25-36 | 19.4 | 28.1 | 25.9 | 31.2 |
| Weeks 37-48 | 27.9 | 30.8 | 31.6 | 32.6 |
| Weeks 49-60 | 32.1 | 33.6 | 29.3 | 38.9 |
| Weeks 61-72 | 36.5 | 39.0 | 37.7 | 44.7 |
The HIT-6 (version 1.0) is a Likert-type, self-reporting questionnaire designed to assess the impact of an occurring headache and its effect on the ability to function normally in daily life. The HIT-6 contains 6 questions, each item was rated from never to always with the following response scores: never = 6, rarely = 8, sometimes = 10, very often = 11, and always = 13. The total score for the HIT-6 was the sum of each response score ranging from 36 to 78. The life impact derived from the total score was described as followed: severe (≥60), substantial (56-59), some (50-55), little to none (≤49).
| units on a scale | Placebo to Eptinezumab 100 mg | Placebo to Eptinezumab 300 mg | Eptinezumab 100 mg to Eptinezumab 100 mg | Eptinezumab 300 mg to Eptinezumab 300 mg |
|---|---|---|---|---|
| Change at Week 36 | -10.01 ± 0.69 | -12.15 ± 0.73 | -10.99 ± 0.57 | -12.0 ± 0.56 |
| Change at Week 48 | -10.71 ± 0.77 | -12.71 ± 0.75 | -12.55 ± 0.59 | -12.68 ± 0.60 |
| Change at Week 60 | -12.54 ± 0.80 | -13.21 ± 0.71 | -12.57 ± 0.56 | -13.15 ± 0.59 |
| Change at Week 72 | -12.68 ± 0.87 | -15.02 ± 0.78 | -13.28 ± 0.63 | -14.13 ± 0.63 |
Collected over Baseline up to Week 72. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo-controlled Period: Placebo | 0/298 (0%) | 3/298 (1%) | 85/298 (28.5%) |
| Placebo-controlled Period: Eptinezumab 100 mg | 0/299 (0%) | 6/299 (2%) | 95/299 (31.8%) |
| Placebo-controlled Period: Eptinezumab 300 mg | 0/294 (0%) | 7/294 (2.4%) | 90/294 (30.6%) |
| Extension Period: Placebo to Eptinezumab 100 mg | 0/145 (0%) | 2/145 (1.4%) | 57/145 (39.3%) |
| Extension Period: Placebo to Eptinezumab 300 mg | 0/148 (0%) | 7/148 (4.7%) | 62/148 (41.9%) |
| Extension Period: Eptinezumab 100 mg to Eptinezumab 100 mg | 0/288 (0%) | 9/288 (3.1%) | 133/288 (46.2%) |
| Extension Period: Eptinezumab 300 mg to Eptinezumab 300 mg | 0/284 (0%) | 9/284 (3.2%) | 118/284 (41.5%) |
| Event | Placebo-controlled Period: Placebo | Placebo-controlled Period: Eptinezumab 100 mg | Placebo-controlled Period: Eptinezumab 300 mg | Extension Period: Placebo to Eptinezumab 100 mg | Extension Period: Placebo to Eptinezumab 300 mg | Extension Period: Eptinezumab 100 mg to Eptinezumab 100 mg | Extension Period: Eptinezumab 300 mg to Eptinezumab 300 mg |
|---|---|---|---|---|---|---|---|
| Inguinal herniaGastrointestinal disorders | 0/298 | 0/299 | 0/294 | 1/145 | 0/148 | 0/288 | 1/284 |
| Colorectal adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/298 | 0/299 | 0/294 | 1/145 | 0/148 | 0/288 | 0/284 |
| Anaphylactic reactionImmune system disorders | 0/298 | 0/299 | 2/294 | 0/145 | 0/148 | 0/288 | 1/284 |
| COVID-19Infections and infestations | 0/298 | 1/299 | 2/294 | 0/145 | 0/148 | 0/288 | 0/284 |
| CholelithiasisHepatobiliary disorders | 0/298 | 1/299 | 0/294 | 0/145 | 1/148 | 0/288 | 0/284 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 0/298 | 0/299 | 1/294 | 0/145 | 1/148 | 0/288 | 0/284 |
| PeriarthritisMusculoskeletal and connective tissue disorders | 0/298 | 0/299 | 0/294 | 0/145 | 1/148 | 0/288 | 0/284 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/298 | 0/299 | 1/294 | 0/145 | 1/148 | 0/288 | 0/284 |
| Eye painEye disorders | 0/298 | 0/299 | 0/294 | 0/145 | 1/148 | 0/288 | 0/284 |
| Chronic sinusitisInfections and infestations | 0/298 | 0/299 | 0/294 | 0/145 | 1/148 | 0/288 | 0/284 |
| Event | Placebo-controlled Period: Placebo | Placebo-controlled Period: Eptinezumab 100 mg | Placebo-controlled Period: Eptinezumab 300 mg | Extension Period: Placebo to Eptinezumab 100 mg | Extension Period: Placebo to Eptinezumab 300 mg | Extension Period: Eptinezumab 100 mg to Eptinezumab 100 mg | Extension Period: Eptinezumab 300 mg to Eptinezumab 300 mg |
|---|---|---|---|---|---|---|---|
| COVID-19Infections and infestations | 16/298 | 19/299 | 15/294 | 25/145 | 31/148 | 63/288 | 63/284 |
| NasopharyngitisInfections and infestations | 3/298 | 5/299 | 9/294 | 7/145 | 13/148 | 19/288 | 27/284 |
| Upper respiratory tract infectionInfections and infestations | 1/298 | 4/299 | 2/294 | 4/145 | 6/148 | 13/288 | 8/284 |
| NauseaGastrointestinal disorders | 4/298 | 4/299 | 5/294 | 1/145 | 5/148 | 2/288 | 3/284 |
| CystitisInfections and infestations | 1/298 | 0/299 | 2/294 | 0/145 | 5/148 | 1/288 | 3/284 |
| Back painMusculoskeletal and connective tissue disorders | 4/298 | 6/299 | 3/294 | 1/145 | 2/148 | 8/288 | 2/284 |
| Urinary tract infectionInfections and infestations | 5/298 | 1/299 | 5/294 | 3/145 | 4/148 | 3/288 | 4/284 |
| MigraineNervous system disorders | 3/298 | 1/299 | 3/294 | 0/145 | 1/148 | 7/288 | 2/284 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/298 | 6/299 | 4/294 | 1/145 | 2/148 | 6/288 | 6/284 |
| PruritusSkin and subcutaneous tissue disorders | 0/298 | 2/299 | 2/294 | 1/145 | 0/148 | 2/288 | 6/284 |
Full analysis set (FAS) included all randomized participants who had a valid baseline assessment and at least 1 valid post-baseline 4-week assessment of monthly migraine days (MMDs) in Weeks 1 to 12.
| Age, Continuous(years) | Placebo | Eptinezumab 100 mg | Eptinezumab 300 mg | Total |
|---|---|---|---|---|
| Mean | 43.8 ± 10.83 | 44.6 ± 10.76 | 43.1 ± 10.2 | 43.8 ± 10.61 |
| Sex: Female, Male(Participants) | Placebo | Eptinezumab 100 mg | Eptinezumab 300 mg | Total |
|---|---|---|---|---|
| Female | 263 | 277 | 260 | 800 |
| Male | 35 | 22 | 33 | 90 |
| Race/Ethnicity, Customized(Participants) | Placebo | Eptinezumab 100 mg | Eptinezumab 300 mg | Total |
|---|---|---|---|---|
| Race — White | 285 | 288 | 281 | 854 |
| Race — Other | 2 | 0 | 0 | 2 |
| Race — Unknown | 11 | 11 | 12 | 34 |
| Race/Ethnicity, Customized(Participants) | Placebo | Eptinezumab 100 mg | Eptinezumab 300 mg | Total |
|---|---|---|---|---|
| Ethnicity — Hispanic or Latino | 0 | 0 | 1 | 1 |
| Ethnicity — Not Hispanic or Latino | 2 | 1 | 2 | 5 |
| Ethnicity — Not collected | 296 | 298 | 290 | 884 |
| Monthly Migraine Days (MMDs)(days/month) | Placebo | Eptinezumab 100 mg | Eptinezumab 300 mg | Total |
|---|---|---|---|---|
| Mean | 13.9 ± 5.72 | 13.8 ± 5.58 | 13.7 ± 5.44 | 13.8 ± 5.57 |
| Monthly Headache Days (MHDs)(days/month) | Placebo | Eptinezumab 100 mg | Eptinezumab 300 mg | Total |
|---|---|---|---|---|
| Mean | 14.5 ± 5.79 | 14.5 ± 5.63 | 14.4 ± 5.45 | 14.5 ± 5.62 |
| Headache Impact Test (HIT-6) Score(units on a scale) | Placebo | Eptinezumab 100 mg | Eptinezumab 300 mg | Total |
|---|---|---|---|---|
| Mean | 66.2 ± 4.38 | 66.6 ± 4.7 | 66.5 ± 4.41 | 66.4 ± 4.5 |
| Percentage of Migraine Attacks With Severe Pain Intensity(percentage of migraine attacks) | Placebo | Eptinezumab 100 mg | Eptinezumab 300 mg | Total |
|---|---|---|---|---|
| Mean | 40.4 ± 29.74 | 47.1 ± 29.82 | 43.9 ± 28.4 | 43.8 ± 29.43 |
6 further baseline measures are reported on the registry.
Showing the first 100 of 138 sites across 17 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes
Ran from Jun 2020 to primary completion in Jul 2021, 13 months.
Results were first posted in Jul 2022, 1 year after primary completion.
Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 13 months is below that.
Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eptinezumab